Catalyst Pharmaceuticals Inc (CPRX)
Solvency ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.21 | 1.19 | 1.18 | 1.22 | 1.25 | 1.23 | 1.11 | 1.12 | 1.15 | 1.12 | 1.11 | 1.10 | 1.13 | 1.12 | 1.18 | 1.18 | 1.28 | 1.24 | 1.24 | 1.19 |
Catalyst Pharmaceuticals Inc's solvency ratios provide insight into the company's ability to meet its long-term financial obligations.
The debt-to-assets, debt-to-capital, and debt-to-equity ratios for all periods are reported as 0.00, indicating that the company has no debt in relation to its assets, capital, and equity. This could signify a conservative capital structure with a lack of financial leverage.
The financial leverage ratio fluctuates over the periods, ranging from 1.10 to 1.28. This ratio indicates the proportion of the company's assets that are financed through debt rather than equity. A ratio above 1 indicates a higher proportion of debt in the capital structure. Catalyst Pharmaceuticals Inc's financial leverage ratio has generally been above 1, peaking at 1.28, suggesting that the company has been utilizing debt as part of its capital structure, albeit modestly.
Overall, the solvency ratios suggest that Catalyst Pharmaceuticals Inc has maintained a low to moderate level of financial leverage and debt relative to its assets, capital, and equity during the periods analyzed.
Coverage ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | — | 67.91 | 68.32 | 51.16 | 24.57 | 63.37 | 174.29 | 644.62 | — | 143.63 | 136.79 | 120.25 | 61.46 | 55.36 | 37.97 | 27.57 | 20.08 | 5.86 | -8.81 | -21.65 |
Interest coverage measures a company's ability to pay its interest expenses on outstanding debt. A higher interest coverage ratio indicates a stronger ability to cover interest payments.
Based on the data provided, Catalyst Pharmaceuticals Inc's interest coverage ratio has exhibited significant fluctuations over the period from December 2019 to December 2023.
In the most recent data point, Catalyst Pharmaceuticals Inc did not report a specific interest coverage ratio for December 2023. However, in the preceding period of September 2023 and June 2023, the company's interest coverage ratios were notably high at 67.91 and 68.32, respectively. This suggests that the company had more than enough earnings to cover its interest expenses during these quarters.
Looking back further, there was a sharp decline in interest coverage in March 2023 to 51.16, which was still at a reasonable level. The largest spike in the interest coverage ratio occurred in June 2022, reaching an exceptionally high level of 644.62, reflecting a significant increase in the company's ability to cover interest payments during that period.
However, the data also shows instances of lower interest coverage ratios in the past, such as in March 2019, when it dropped to 5.86, and in June 2019 and March 2019, where it fell into negative territory (-8.81 and -21.65, respectively). This indicates potential difficulties in meeting interest obligations with earnings during those quarters.
Overall, the trend in Catalyst Pharmaceuticals Inc's interest coverage ratio demonstrates variability, with some periods of strong coverage and other periods where the company may have faced challenges in meeting its interest obligations from earnings alone. Further analysis of the company's financial and operational performance is recommended to better understand the factors driving these fluctuations in interest coverage.